For UnitedHealth Group Inc. (NYSE: UNH), the early effect of coronavirus on its business was a marked reduction in costs due to
UnitedHealth Group (UNH) is headed for a weak second half. Here’s why
Categories
pharmaceuticals
Bristol Myers looks to expand cardiovascular portfolio with MyoKardia acquisition
Bristol Myers Squibb (NYSE: BMY) agreed to acquire MyoKardia Inc. (NASDAQ: MYOK) for $13.1 billion in cash. The deal, which amounts to
After initial hiccups, Cigna (CI) looks to emerge healthier post-COVID
The healthcare sector was required to respond to the coronavirus outbreak in a proactive manner, unlike most other businesses. Cigna Corporation (NYSE:
AMAG Pharmaceuticals Inc (AMAG) Q2 2020 Earnings Call Transcript
AMAG Pharmaceuticals Inc (NASDAQ: AMAG) Q2 2020 earnings call dated August 06, 2020 Corporate Participants: Rushmie Nofsinger -- Executive Director of Corporate Communications &
What makes CVS Health a better investment option than Walgreens
https://www.youtube.com/watch?v=WOSh4S0zUds For healthcare systems across the world, currently, the first priority is to find an effective treatment for coronavirus, at a time
Rite Aid Corp (RAD) Q2 2021 Earnings Call Transcript
Rite Aid Corp (NYSE: RAD) Q2 2021 earnings conference call dated September 24, 2020 Corporate Participants: Trent Kruse -- Senior Vice President of
Rite Aid’s (RAD) loss narrows in Q2 2021
Rite Aid Corporation (NYSE: RAD) reported a narrower loss in the second quarter of 2021. Net loss shrank to $0.25 per share
Aurora Cannabis (ACB) banks on premium brands after disastrous Q4
Shareholders of Aurora Cannabis (NYSE: ACB) were dealt an unexpected blow this week as the pot company's disappointing earnings report thwarted hopes
Aurora Cannabis Inc. (ACB) Q4 2020 Earnings Call Transcript
Aurora Cannabis Inc (NYSE: ACB) Q4 2020 earnings call dated Sep. 22, 2020 Corporate Participants: Miguel Martin -- Chief Executive Officer and Chief Commercial
Highlights of Aurora Cannabis (ACB) Q4 2020 earnings report
Aurora Cannabis, Inc. (NYSE: ACB) reported a wider loss for the fourth quarter of 2020, hurt by a 5% decrease in revenues.
ERYTECH Pharma S.A. (ERYP) Q2 2020 Earnings Call Transcript
ERYTECH Pharma S.A. (NASDAQ: ERYP) Q2 2020 earnings call dated Sep. 22, 2020 Corporate Participants: Gil Beyen -- Chief Executive Officer Eric Soyer -- Chief Financial
Moderna (MRNA) set to take advantage of opportunity in vaccines
Shares of Moderna Inc. (NASDAQ: MRNA) have gained 246% since the beginning of this year and more than 279% over the past
Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why
Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through
Humana (HUM) can offer long-term returns despite high valuation
https://www.youtube.com/watch?v=zOVB6xD8rS4 There has been a marked decrese in the number of people seeking healthcare services since the virus outbreak but most healthcare
COVID-19 vaccine development: A look at some of the pharma companies and their progress
The COVID-19 pandemic continues to go on and while the world is slowly coming out of the previously imposed strict lockdown, things
Medtronic (MDT) revisits business strategy even as recovery gathers steam
https://www.youtube.com/watch?v=ukh0vaOtvBw For Medtronic plc (NYSE:MDT), the last two quarters were disappointing as healthcare institutions postponed routine medial procedures and channeled their resources
Will da Vinci power help Intuitive Surgical (ISRG) beat COVID blues?
Being part of a rapidly growing industry and having a successful business model can be a winning combination in difficult times like
Stable demand should help PetMed (PETS) emerge stronger from pandemic
PetMed Express (NASDAQ: PETS) has been around for a long time, expanding its foothold in the lucrative pet care market at a
CureVac (CVAC): Another COVID-19 stock that attracted investors
In recent times, investors have been betting on the biotech companies that are in the race to develop the COVID-19 vaccine. The
Veru Inc. (VERU) Q3 2020 Earnings Call Transcript
Veru Inc. (NASDAQ: VERU) Q3 2020 earnings call dated Aug. 13, 2020 Corporate Participants: Samuel Fisch -- Director, Investor Relations Mitchell Steiner -- Chairman, President, and
Inovio (INO) aims to produce 100 million doses of COVID-19 vaccine in 2021
Shares of INOVIO (NASDAQ: INO) were down over 23% on Tuesday, a day after the company reported second quarter 2020 earnings results